Xeris Biopharma Holdings
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Xeris Biopharma Holdings generated cash of -$102,891,000, which is less than the previous year. Cash used in financing activities reached the amount of $127,473,000 last year. Net change in cash is therefore $59,043,000.
Cash Flow
| 2016 | -16.08M | -35K | 3.90M |
|---|---|---|---|
| 2018 | -56.27M | -68.26M | 128.21M |
| 2021 | -102.89M | 34.46M | 127.47M |
XERS Cash Flow Statement (2017 – 2022)
| 2022 | 2019 | 2017 | |
|---|---|---|---|
Cash at beginning of period | 67.27M | 42.04M | 44.48M |
Operating activities | |||
Net income | -94.66M | -60.08M | -13.20M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||
Depreciation and amortization | 12.66M | 320K | 116K |
Stock-based compensation expense | 11.38M | 1.72M | 540K |
| Deferred income tax benefit | 11.38M | 1.72M | 540K |
| Changes in operating assets and liabilities: | |||
Accounts receivable, net | -13.37M | -1.67M | 204K |
Inventories | -7.46M | 4.04M | -846K |
Accounts payable | -4.31M | -1.11M | -2.90M |
Cash generated by operating activities | -102.89M | -56.27M | -16.08M |
Investing activities | |||
Purchases Of Investments | -43.02M | -68.85M | 0 |
Investments In Property Plant And Equipment | -524K | -1.51M | -35K |
Acquisitions Net | 38.46M | 0 | 0 |
Cash generated by investing activities | 34.46M | -68.26M | -35K |
Financing activities | |||
Common Stock Issued | 27M | 98.32M | 71K |
Payments for dividends | 0 | 0 | 0 |
Repurchases of common stock | -534K | 0 | 0 |
Repayments of term debt | 0 | 35M | -32K |
Cash used in financing activities | 127.47M | 128.21M | 3.90M |
Net Change In Cash | 59.04M | 3.67M | -12.21M |
Cash at end of period | 126.31M | 45.71M | 32.26M |
| Data source | Data source |